

MiNA Therapeutics to present at Jefferies 2021 London Healthcare Conference

London, United Kingdom, 12 November 2021 – MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (saRNA) therapeutics, announces that its Chief Executive Officer, Robert Habib, will present and host one-on-one meetings at the [Jefferies 2021 London Healthcare Conference](#), taking place from 16-19 November 2021 in-person and virtually.

MiNA’s presentation will take place at 3:40pm GMT on Tuesday, 16 November 2021, with a live webcast available via the following link: <https://wsw.com/webcast/jeff201/mina/1827270>.

Mr Habib will introduce MiNA and its saRNA technology platform, as well as provide an update on the Company’s clinical progress and strategy.

About MiNA Therapeutics

MiNA Therapeutics is the leader in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a revolutionary new class of medicines that can restore or boost normal function in patients’ cells. We are advancing a proprietary pipeline of new medicines with an initial focus on cancer and genetic diseases, while collaborating with leading pharmaceutical companies to apply our technology platform across a broad range of therapeutic areas. Based on our unique know-how in RNA activation we are expanding the possibilities of RNA-based medicine for patients. www.minatx.com

Contact:

MiNA Therapeutics
Robert Habib, CEO / Robin Wright, CFO
Phone: +44 208 811 6700
E-Mail: info@minatx.com

Media requests:

Victoria Foster Mitchell / Tim Stamper
FTI Consulting
Phone: +44 203 727 1000
E-Mail: MiNATherapeutics@fticonsulting.com